'Dimmer switch' drug idea could tackle schizophrenia

August 11, 2014, Monash University
“Dimmer switch” drug idea could tackle schizophrenia

(Medical Xpress)—Discovery of a new mechanism of drug action could lead to the next generation of drugs to treat schizophrenia.

Affecting one per cent of the world's population, is a major health condition. It affects a person's ability to think, feel and act and is associated with distressing symptoms including hallucinations and delusions.

New Monash University findings, published today in the journal, Nature Chemical Biology, offer hope of a new class of drug that can act as a "" to control schizophrenia, without causing some of the common side effects associated with current anti-psychotic medicines.

One of the lead researchers of the study, Dr Rob Lane from the Monash Institute for Pharmaceutical Sciences (MIPS) said all current anti-psychotic medicines block the action of dopamine, a neurotransmitter, at a brain protein called the dopamine D2 receptor, resulting in serious side effects.

"These medications frequently result in serious side effects because this protein is also important for the control of movement. The side-effects can sometimes persist even after the patient has stopped taking the medication," Dr Lane said.

Co-lead researcher Professor Arthur Christopoulos, said gaining a better understanding of the biology of schizophrenia will lead to more effective drugs.

"The idea behind our research is to develop a drug that doesn't completely block dopamine. We found a molecule that, rather than blocking the effect of dopamine at the D2 receptor, acts to subtly dial down 's effect, a bit like a dimmer switch," Professor Christopoulos said.

"This means that if we can get just the right amount of dial-down, we could treat the symptoms of the disease and avoid some of these .

"We're a long way yet from developing a drug, but our dimmer switch approach to controlling schizophrenia means it's conceivable we could have a whole new class of anti-psychotics in the future."

The research team also found a unique twist with the molecule, its mechanism of action changed depending on the arrangement of the D2 receptor in the brain.

Dr Lane said not only does this represent a new approach to develop anti-psychotics, it gives researchers more information about the protein involved in the disease.

"This extra information will help researchers develop new drugs that target the protein," Dr Lane said.

The next phase of the research will see Dr Lane and Professor Christopoulos collaborate with chemists at MIPS to try to develop a better version of the used in the study.

Explore further: Improving the search for new schizophrenia treatments

More information: A new mechanism of allostery in a G protein-coupled receptor dimer, Nature Chemical Biology, DOI: 10.1038/nchembio.1593

Related Stories

Improving the search for new schizophrenia treatments

April 5, 2013
(Medical Xpress)—Controlling the symptoms of schizophrenia is the job of antipsychotic drugs which block a set of specific neural signals. But the way these drugs work can lead to a host of severe and debilitating long-term ...

Scientists unlock potential heart attack drug without side effects

March 11, 2014
(Medical Xpress)—Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.

New knowledge on the pharmacology of dopamine stabilizers

February 24, 2012
A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease – pridopidine or dopamine stabiliser ACR16 – might operate via previously unknown mechanisms of action. Researchers have ...

New discovery in quest for better drugs

October 14, 2013
Scientists have combined cutting edge computer modelling with pharmacology and medicinal chemistry to reveal new insights into how the body interacts with novel drug treatments, in research that could lead to the creation ...

Research may explain why some people with schizophrenia do not respond to treatment

November 29, 2012
(Medical Xpress)—New research suggests that the molecular mechanism leading to schizophrenia may be different in patients who fail to respond to anti-psychotic medication compared to patients who do respond.

Gene variant linked to schizophrenia, bipolar disorder and alcoholism

July 22, 2014
A rare gene variant discovered by UCL (University College London) scientists is associated with an increased risk of developing schizophrenia, bipolar disorder and alcoholism, confirms new research.

Recommended for you

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

Scientists unleash power of genetic data to identify disease risk

January 16, 2018
Massive banks of genetic information are being harnessed to shed new light on modifiable health risks that underlie common diseases.

Blood-vessel-on-a-chip provides insight into new anti-inflammatory drug candidate

January 15, 2018
One of the most important and fraught processes in the human body is inflammation. Inflammatory responses to injury or disease are crucial for recruiting the immune system to help the body heal, but inflammation can also ...

Molecule produced by fat cells reduces obesity and diabetes in mice

January 15, 2018
UC San Francisco researchers have discovered a new biological pathway in fat cells that could explain why some people with obesity are at high risk for metabolic diseases such as type 2 diabetes. The new findings—demonstrated ...

Obese fat becomes inflamed and scarred, which may make weight loss harder

January 12, 2018
The fat of obese people becomes distressed, scarred and inflamed, which can make weight loss more difficult, research at the University of Exeter has found.

Optimized human peptide found to be an effective antibacterial agent

January 11, 2018
A team of researchers in the Netherlands has developed an effective antibacterial ointment based on an optimized human peptide. In their paper published in the journal Science Translational Medicine, the group describes developing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.